Drug Landscape ›
Rivaroxaban 2.5mg ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 8
Most-reported reactions
Haemorrhage — 1 report (12.5%) Incision Site Haemorrhage — 1 report (12.5%) Muscle Graft — 1 report (12.5%) Post Procedural Complication — 1 report (12.5%) Pulmonary Mass — 1 report (12.5%) Red Blood Cell Count Decreased — 1 report (12.5%) Tumour Excision — 1 report (12.5%) Wound — 1 report (12.5%)
Source database →
Rivaroxaban 2.5mg in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Rivaroxaban 2.5mg approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Rivaroxaban 2.5mg in United States?
Asan Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.